Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Essential Healthcare News.
Press releases published on October 18, 2025
JointCommerce Launches A21+ ‘Household Targeting’ Solution for Connected TV Video Advertising
LOS ANGELES, CA, UNITED STATES, October 18, 2025 /EINPresswire.com/ -- JointCommerce, a leading ad-tech and media platform connecting brands with verified A21+ cannabis consumers, today announced the launch of JointCommerce Household Targeting, a …
Barry I. Gold to Present Groundbreaking ‘We’re Overdosed’ Series at Frankfurt Buchmesse 2025
Author of the “We’re Overdosed” series to hold an exclusive signing and global awareness event in Frankfurt. CENTENNIAL, CO, UNITED STATES, October 18, 2025 /EINPresswire.com/ -- Barry I. Gold, author of We’re Overdosed and We’re Overdosed: From Opium …
A Million Thanks Launches New Veteran Letter Request Program for Post-9/11 Veterans
For the first time, veterans can request free bundles of handwritten letters promoting gratitude, hope, and mental well-being. TOPEKA, KS, UNITED STATES, October 18, 2025 /EINPresswire.com/ -- A Million Thanks®, the national nonprofit known for sending …
Dr. Kaushal Kakkad Honored with Doctor of Philosophy in Marketing and Innovation by Kennedy University
Summirow Dental CEO Kaushal Kakkad earns honorary PhD, recognized for innovation in healthcare marketing, patient care, and dental industry leadership. SURAT, GUJARAT, INDIA, October 19, 2025 /EINPresswire.com/ -- Introduction On October 4, 2025, …
Evoq Technologies Appoints Benjamin A. Bakall, MD, PhD as Scientific Advisor and Principal Investigator
LAS VEGAS, NV, UNITED STATES, October 18, 2025 /EINPresswire.com/ -- Evoq Technologies today announced the appointment of Benjamin A. Bakall, MD, PhD as a Scientific Advisor and Principal Investigator for upcoming clinical studies with the Twilight™ Dark …
Evoq Technologies’ Breakthroughs in Retinal Diagnostics at AAO Annual Meeting
Visit us at the AAO in Orlando Florida, Oct 17-thru the 20th, booths 411 and 523 LAS VEGAS, NV, UNITED STATES, October 18, 2025 /EINPresswire.com/ -- Evoq Technologies is rapidly emerging as one of the most exciting companies in vision science, fueled …
New Book: Experiencing Transcendence Reimagines Addiction & Trauma Recovery Moving Beyond Lifelong Struggle to Freedom
Addiction Recovery Expert Richard Taite and Constance Scharff, PhD, Introduce a Sixth Stage of Recovery With Practical Tools for Post-Traumatic Growth NEW YORK, NEW YORK, UNITED STATES, October 18, 2025 /EINPresswire.com/ -- Can you truly recover from …
We’re Overdosed: From Opium to Opioids Reveals the Hidden Roots of Addiction
Barry I. Gold connects the global opium trade to modern pharmaceutical dependency and calls for systemic control. CENTENNIAL, CO, UNITED STATES, October 18, 2025 /EINPresswire.com/ -- We’re Overdosed: From Opium to Opioids by Barry I. Gold (Sweetspire …
The Untold Story of America’s Opioid Epidemic Uncovers the Truth Behind the Crisis
Barry I. Gold’s searing exposé combines investigative journalism and human storytelling to demand empathy, reform, and accountability. CENTENNIAL, CO, UNITED STATES, October 18, 2025 /EINPresswire.com/ -- We’re Overdosed: The Untold Story of America’s …
Rozelle’s Soothing Care Dental Earns QIP Accreditation for Outstanding Practice Standards
Soothing Care Dental in Rozelle marks a new milestone in quality care, achieving national QIP Accreditation for trusted dental care. SYDNEY, NSW, AUSTRALIA, October 18, 2025 /EINPresswire.com/ -- Soothing Care Dental announces QIP Accreditation, a …
NuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor-Infiltrating Lymphocytes at the ESMO Congress 2025
NUC-7738 Synergizes with PD-1 Inhibitors to Promote Cancer Cell Death Data Reinforces Mechanism of Action along with Efficacy and Safety Profile of NUC-7738 BERLIN, Oct. 18, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) …
Precede Biosciences Presents New ESMO 2025 Data Demonstrating Its Liquid Biopsy Platform’s Ability to Resolve Target Expression and Molecular Subtypes in Small Cell Lung Cancer
Small cell lung cancer (SCLC) accounts for 15% of all lung cancers and remains an aggressive disease with median survival of approximately 12 months for patients with extensive-stage disease Precede Bio’s platform combines comprehensive epigenomic …
ITM Announces Phase 3 COMPETE Data Demonstrating a Statistically Significant Higher Objective Response Rate with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus in Patients with Gastroenteropancreatic Neuroendocrine Tumors at ESMO 2025
Study data also showed prolonged progression-free survival with 177Lu-edotreotide compared to everolimus across patient subgroups Berlin, Germany, October 18, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, …
Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial
PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial is fully enrolled Additional analysis of data from a Phase 1b clinical trial that included all patients treated with gedatolisib combined with fulvestrant and palbociclib showed median …
Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration Resistant Prostate Cancer (“mCRPC”)
Median radiographic progression free survival (“rPFS”) was 9.1 months and the six-month rPFS rate was 67% No patients discontinued study treatment due to a treatment-related adverse event (“TRAE”) MINNEAPOLIS, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc …
Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer
Clinical benefit of the gedatolisib regimens was consistent across patient subgroups Hyperglycemia was reported in only 9.2% of patients treated with gedatolisib + palbociclib + fulvestrant (“gedatolisib triplet”) and in 11.5% of patients treated with …
Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs at the 2025 European Society for Medical Oncology (ESMO) Congress
FTI mechanism addresses innate and adaptive resistance pathways common to targeted oncology therapies Early clinical and preclinical data support darlifarnib’s potential to enhance clinical benefit of PI3Kα-, KRAS- and tyrosine kinase inhibitors 50% …
AdvanCell’s 212Pb-ADVC001 demonstrates encouraging safety and compelling anti-tumor activity in Phase 1b in prostate cancer
Results from the TheraPb Phase 1b dose escalation presented at ESMO 2025 show a promising therapeutic index for 212Pb-ADVC001 in patients with metastatic castration-resistant prostate cancer (mCRPC) No dose-limiting toxicities and no treatment-related …